.jpg)
First-Ever Study, Showing In-Vivo Systemic Administration of a MicroRNA Therapeutic in Liver Cancer, With a Two-Fold Decrease in Tumor-Mass and a Dramatic Suppression of the Targeted MicroRNA
May Benefit Over 19,000 Liver Cancer Patients Annually in the US; 5-Year Survival Under 10%